Literature DB >> 12726955

Enfuvirtide approved for defusing HIV.

Adrian Burton.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12726955     DOI: 10.1016/s1473-3099(03)00620-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.

Authors:  Yael Wexler-Cohen; Avraham Ashkenazi; Mathias Viard; Robert Blumenthal; Yechiel Shai
Journal:  FASEB J       Date:  2010-07-06       Impact factor: 5.191

3.  Blocking HIV-1 entry by a gp120 surface binding inhibitor.

Authors:  Lun K Tsou; Chin-Ho Chen; Ginger E Dutschman; Yung-Chi Cheng; Andrew D Hamilton
Journal:  Bioorg Med Chem Lett       Date:  2012-03-02       Impact factor: 2.823

4.  Peptide Amphiphilic-Based Supramolecular Structures with Anti-HIV-1 Activity.

Authors:  Maria J Gómara; Ramon Pons; Carolina Herrera; Paul Ziprin; Isabel Haro
Journal:  Bioconjug Chem       Date:  2021-07-13       Impact factor: 4.774

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.